Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Quebec platelet syndrome (QPS) is a platelet granule disorder characterized by moderate to severe bleeding after trauma, surgery or obstetric interventions, frequent ecchymoses, mucocutaneous bleeding and muscle and joint bleeds.
Features include: Menorrhagia, Bruising susceptibility, Joint hemorrhage, and Impaired epinephrine-induced platelet aggregation and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Impaired epinephrine-induced platelet aggregation, Low platelet count (thrombocytopenia) |
PLAU function has not been fully characterized.
Quebec platelet disorder has been associated with mutations in the PLAU gene on chromosome 10.
Genetic testing for PLAU is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for Quebec platelet disorder has been reported in the published literature.
No clinical trials have been registered for Quebec platelet disorder.
10 publications have been identified in PubMed for Quebec platelet disorder. Research spans Case Report / Case Series (40%), Review / Meta-Analysis (30%), and Diagnostic / Biomarker (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 4 | 40% |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 3:41 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Quebec platelet disorder
1 |
Joint hemorrhage |
3 |
30% |
Testing and diagnosis research | 2 | 20% |
Laboratory research | 1 | 10% |
Hayward CPM (2026). [PMID: 41968845](https://pubmed.ncbi.nlm.nih.gov/41968845/). *Int J Lab Hematol*. [Review / Meta-Analysis]
Su Y (2026). [PMID: 42103294](https://pubmed.ncbi.nlm.nih.gov/42103294/). *Semin Thromb Hemost*. [Case Report / Case Series]
Isaksen MY (2026). [PMID: 42118933](https://pubmed.ncbi.nlm.nih.gov/42118933/). *Tidsskr Nor Laegeforen*. [Case Report / Case Series]
Broojerdi MH (2025). [PMID: 40651280](https://pubmed.ncbi.nlm.nih.gov/40651280/). *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis*. [Basic Science / Preclinical]
Mehic D (2025). [PMID: 40288411](https://pubmed.ncbi.nlm.nih.gov/40288411/). *Hamostaseologie*. [Review / Meta-Analysis]
Mathews N (2025). [PMID: 40302228](https://pubmed.ncbi.nlm.nih.gov/40302228/). *International journal of laboratory hematology*. [Case Report / Case Series]
Al-Ghafry M (2025). [PMID: 39299257](https://pubmed.ncbi.nlm.nih.gov/39299257/). *Semin Thromb Hemost*. [Review / Meta-Analysis]
Al Dawood R (2025). [PMID: 40796410](https://pubmed.ncbi.nlm.nih.gov/40796410/). *Pathology*. [Diagnostic / Biomarker]
Zabeida A (2025). [PMID: 40778015](https://pubmed.ncbi.nlm.nih.gov/40778015/). *Research and practice in thrombosis and haemostasis*. [Case Report / Case Series]
Safdari SM (2025). [PMID: 41316200](https://pubmed.ncbi.nlm.nih.gov/41316200/). *Thrombosis journal*. [Diagnostic / Biomarker]